Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744907 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL11857583 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL28070085 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL11512940 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL11865856 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL9244508 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL2428839 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL4334523 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL7208906 | 0.98 | TSHR (0.61) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL5098798 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024390-B1 | INSULIN DERIVATIVE | NOVO NORDISK AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-8796205-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2014-08-05 | — | — | US | disclosed |
| US-20090105121-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-2024390-A1 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007128815-A1 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
| US-6452039-B1 | PROSTANOIC ACID DERIVATIVE WHEREIN THE ALPHA CHAIN HAS EIGHT OR MORE SKELETAL CARBON ATOMS; EXTREMELY STRONG ACTION; HYPERTENSION, ASTHMA, DIABETES, ARTERIAL SCLEROSIS, RENAL FAILURE, CARDIAC INFARCTION, ANGINA PECTORIS | SUCAMPO AG (CH) | 2002-09-17 | — | — | US | disclosed |
| EP-0857718-B1 | ENDOTHELIN ANTAGONIST | SUCAMPO AG (CH) | 2002-08-14 | — | — | EP | disclosed |
| US-6242485-B1 | ADMINISTERING PROSTANOIC ACID DERIVATIVE TO TREAT VISION, KIDNEY, CARDIOVASCULAR AND BRAIN DISORDERS; HYPOTENSIVE AND ANTIASTHMATIC AGENTS | R-TECH UENO (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-0857718-A1 | ENDOTHELIN ANTAGONIST | R-Tech Ueno, Ltd. (JP) | 1998-08-12 | — | — | EP | disclosed |
| US-3993773-A | Control of mites with esters of cyclopropane substituted carboxylic acids | ZOECON CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
| US-3969384-A | Esters of cyclopropane alkanoic acids | ZOECON CORPORATION (US) | 1976-07-13 | — | — | US | disclosed |
| US-3960907-A | MITICIDES | ZOECON CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105121-A1 | Insulin Derivative | INSR, IAPP, GPR119 | TSHR 196/4885LMNA 2327/4885ALDH1A1 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.